0 0 0
This online shop is using cookies to give you the best shopping experience. Thereby for example the session information or language setting are stored on your computer. Without cookies the range of the online shop's functionality is limited. If you don't agree, please click here.

Kaufman, Mehnert Melanoma

ISBN: 978-3-319-22538-8

Edition: 1st Ed.

Publication date: December 2015

Cover: Hardcover

Pages: 477 p.

Illustrations: 36 ill.

Publisher: Springer

Delivery times, dependent on availability and publisher: between 2 and 14 days from when you complete the order.

Description

  • Concise, up-to-date overview of the diagnosis, treatment, and prevention of melanoma
  • Reviews advances in basic science
  • Covers current and evolving treatment strategies in the adjuvant, metastatic, and preventive settings
  • Discusses the treatment of special populations and rare variants

Melanoma is one of the most types of cancer. When melanoma is detected at an early stage, treatment is highly successful, but outcomes can be poor when the disease is advanced. There has been significant progress in our understanding of the molecular biology, genetics, and immunology of melanoma over the past decade. This has been accompanied by rapid advances in therapeutic strategies for patients with melanoma. This book provides the clinician and the researcher with a broad understanding of the molecular and cellular pathogenesis of melanoma, explores the clinical characteristics and criteria for clinical and pathological staging of the disease, and provides an overview of current and evolving treatment strategies in the adjuvant, metastatic, and preventive settings. The treatment of special populations and rare variants of melanoma that often present particular clinical challenges is also covered. Authored by international experts in melanoma biology and clinical management, this volume concisely explains how to diagnose, treat, and prevent melanoma while reviewing advances in basic science and providing an overview of innovative approaches still under development.